Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prometheus Laboratories, a specialty pharmaceutical and diagnostic company, has received the New York state's approval for Prometheus IBS Diagnostic, reported to be the first and only blood test for irritable bowel syndrome.
Subscribe to our email newsletter
According to the company, this novel test incorporates 10 biomarkers, two of which are proprietary, along with a proprietary algorithm to help physicians diagnose patients with irritable bowel syndrome (IBS).
Henry Pan, chief scientific and medical officer of Prometheus, said: “Prometheus IBS Diagnostic is a valuable tool that can help accelerate the diagnosis and treatment of IBS. We have worked diligently with the New York State Department of Health to ensure that this innovative test is broadly available to patients in need.”